Anders Wiklund resigns from the Board of Peptonic Medical

Stockholm, November 20, 2015. Peptonic Medical AB (publ) – a company developing pharmaceuticals based on oxytocin – announces today the resignation of  Mr Anders Wiklund  from its Board .

After Anders Wiklund’s resignation, the Board consists of four members.

“We thank Anders Wiklund for his commitment and invaluable support to the company during his time on the Board. The search for a replacement has started and we will revert to this matter at the Annual General Meeting in the spring of 2016”, says Johan Inborr, CEO.

For further information, please contact:

Johan Inborr, CEO

Phone: +46 708 853 893


About Peptonic Medical AB (publ)

Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)’s mission is to develop safe and effective drugs based on oxytocin.


Documents & Links